The International Heart Forum Beijing 2006 will be held on August 18-21, 2006 at

BEIJING INTERNATIONAL CONVENTION CENTER

8, Beichendonglu Chaoyang District Beijing 100101

Cardiology

Honorary Chairpersons: Gao Runlin Hu Dayi Huang Congxin Zhang Yun

Chairpersons: Yang Yuejin Hui Rutai Yong J.Geng ( USA ) Alan Yeung ( USA )

Co-Chairpersons: Huang Dejia Zhu Jun Li Weimin Zhu Dingliang Li Yishi

Secretary General: Pu Jielin Li Jianjun Han Yaling Zhu Zhiming Hua Wei

Honorary Consultants (Sorted in alphabetic order of family names)

Organizing Committee

Chairpersons: Huo Yong Chen Jilin Ma Aiqun

Secretary: Zhang Jian

Members (Sorted in alphabetic order of family names)

Scientific Committee

Chairpersons: Ge Junbo Zhang Shu Liao Yuhua

Secretary General: Gao Zhan

Members (Sorted in alphabetic order of family names)

Chinese Faculty (Sorted in alphabetic order of family name)

International Faculty (Sorted in alphabetic order of family names)

Main Topics

1. Coronary Heart Disease

1.1 Inflammation and a therosclerotic p laque r upture

1.2 Ventricular r emodeling p ost m yocardial i nfarction

1.3 New c linical t herapeutic a pproaches in MI

1.4 Brain n atriuretic p eptide and ACS

1.5 Risk a ssessment and m anagement in ACS

1.6 Stunning, h ibernation and p reconditioning

1.7 Thrombosis t hrombolysis and b leeding: t herapeutic and p rognostic i mplication

1.8 Angiogenesis and c ollateral f ormation

1.9 Stem c ell t herapy in i schemic h eart d isease

1.10 Clinical a pplications of c oronary f low r eserve

1.11 Endothelial d ysfunction: b asic and c linical a spects

1.12 Antiplatelet t herapy for c oronary h eart d isease

1.13 Ups and d owns of g ene t herapy

1.14 Current s tatus of i schemic r eperfusion

1.15 No-reflow p henomenone: m echanisms and t herapeutics

1.16 Drug t herapy after p ercutaneous c oronary i ntervention

1.17 Prognostic i ndex of ACS

1.18 Diabetics and c oronary h eart d isease

1.19 Current s tatus of c oronary m icrovessel d isease

1.20 Strategies of t hrombolysis t herapy

1.21 Conventional and n ew r isk f actors in CHD

1.22 Inflammatory h eart d isease

1.23 Injury r ecovery and p rotection for v essel w all

1.24 Resistance to a spirin and c lopidogrel

1.25 Markers in ACS

2.Hypertension

2.1 Functional Genomics and Pharmacogenomics of Hypertension

2.2 Current Treatment Strategies for Human Essential Hypertension

2.3 Non-Pharmacological Treatments for Hypertension

2.4 Target Organ Damage

2.5 Mechanisms of Cardiac Hypertrophy and Remodeling

2.6 Mechanisms of Vascular Dysfunction in Hypertension

2.7 PAD and hypertension

2.8 Hypertension and Stroke

2.9 Hypertension in the Elderly

3.Heart Failure

3.1 ACEI vs. ARB in Congestive Heart Failure

3.2 Biventricular Pacing for Congestive Heart Failure

3.3 Advancement in Refractory Congestive Heart Failure

3.4 Apnea and Congestive Heart Failure

3.5 Early Diagnosis and Prediction in Congestive Heart Failure

3.6 Risk Stratification for Congestive Heart Failure

3.7 BNP in Diagnosis and Therapy of Congestive Heart Failure

3.8 Diabetes and Heart Failure

3.9 Diastolic Heart Failure: Diagnosis, Etiology and Treatment

3.10 Heart Transplantation and Pathologic Process

3.11 Non-medicine Treatment of Cardiac Diseases

3.12 Thyropathy and Cardiac Diseases

3.13 Diagnosis and Treatment of Acute Heart Failure

3.14 Study Progress of Cardiomyopathy

3.15 Heart Failure and BNP

3.16 Progress in Molecular Biology of Heart Failure

3.17 Application of ECMO in Severe Heart Failure

3.18 Progress of h eart f ailure in m edicine t reatment

3.19 Application of ?–blockers in h eart f ailure

4.Drugs Therapy in Cardiovascular Disease

4.1 Ten Years Study of Characteristics of Heart Failure in Taiwan

4.2 Drug Study about hERG, QT Interval Prolongation and Torsades de Pointes

4.3 How to Design Cardiovascular Medical Device Clinical Trial?

4.4 Clinical Therapy and Basic Research on renal Hypertension

4.5 Therapeutics of Personalized Medicine with Oriented Gene

4.6 Clinical Therapy of Cardiovascular Drugs for Adverse Reactions (ADR) Monitoring

4.7 Study about the T herapeutic Dose of TNK-tPA on the Fibrinolysis

4.8 Effect of Ibutilide Injection on QTc Interval in Defibrillating AFL/AF

4.9 The Value of Brain Natriuretic Peptide in Evaluating Severities and Predicting Prognosis in Patients with Chronic Heart Failure

4.10 The Evaluating Dbout Aifferent a nti-hypertentive Drugs by ABPM

4.11 Diagnosis and Differentiation of Noncompaction of the Left Ventricular Myocardium

4.12 Changes of Standing Blood Pressure in Hypertension Patients Treated with Medication

5. Pulmonary Circulation

5.1 Cardiopulmonary Resuscitation and Emergency m edicine

5.2 Cardiac e mergencies and Emergency Cardiovascular Care

5.3 Advance in c ardiopulmonary r esuscitation

5.4 Differential d iagnosis and t reatment in s evere a rrhythmia

5.5 New Concepts in Pathogenic m echanism of PAH

5.6 Diagnosis and m anagement s trategy in PAH

5.7 Right h eart c atherization in PAH

5.8 The e pidemiology, r isk f actors, r isk s tratification and p revention of Pulmonary Embolism

5.9 New d iagnosis m ethods in Pulmonary Embolism

5.10 Pharmacological t reatment and i nterventional p rocedure in Pulmonary Embolism in China

5.11 Obstructive s leep a pnea s yndrome and c ardiovascular d iseases

5.12 Advances in the Pathogenesis and Treatment of Pulmonary Artery Hypertension

5.13 Differentiating Diagnosis of Pulmonary Artery Hypertension

5.14 Ventavis TM: The Lung-Selective Therapy for Pulmonary Hypertension

5.15 Pulmonary Thromboembolism in China : Current Status and Future Strategy

5.16 Guideline and Progress in Deep Venous Thrombosis

5.17 Interventional Treatment of Pulmonary Thromboembolism

5.18 Classification of Pulmonary Hypertension in China from Fu Wai Hospital

5.19 Pathology of Pulmonary Hypertension

5.20 Pulmonary Hypertension and Surgery

5.21 Pulmonary Hypertension and Rheumatic Diseases

5.22 RICU of Pulmonary Vascular Diseases

5.23 Molecular Mechanism of Idiopathic VTE

6. Cardiovascular Emergency

6.1 Major Changes in the 2005 AHA Guidelines for CPR and ECC

6.2 Evidence, e valuation and m anagement of h ot s pot in p rocessing of 2005 CPR g uidelines

6.3 Optimal v asopressor a gents d uring CPR

6.4 Non-cardiogenic c ardiac a rrest

6.5 Management of a cute a rrhythmias

6.6 The u sage of a nti-arrhythmic d rugs during CPR

6.7 Anti-coagulation t herapy in ACS: u pdate

6.8 Anti-infection t herapy in c ritical ill p atients

6.9 Management of r efractory h eart f ailure

6.10 Blood p urification in p atients with s evere h eart d isease and r enal f ailure